Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

The value of patient-reported outcomes in early-phase clinical trials

Nature Medicine volume 28, pages 18–20 (2022)Cite this article

Subjects

If used correctly, patient-reported outcomes can provide preliminary evidence of efficacy and tolerability from a patient perspective, as well as supporting regulatory review.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Patient-reported outcomes in early-phase trials.
Fig. 2: Strategy for patient-reported outcome assessment.

References

  1. US Food and Drug Administration (FDA). The Drug Development Process–Step 3: Clinical Research; https://www.fda.gov/patients/drug-development-process/step-3-clinical-research (FDA, 2018).

  2. Coleman, R. L. et al. Oncology 99, 444–453 (2021).

    Article  Google Scholar 

  3. Basch, E. & Dueck, A. C. Exp. Opin. Drug Discov. 11, 753–758 (2016).

    Article  CAS  Google Scholar 

  4. Fiteni, F. et al. BMC Cancer 19, 361 (2019).

    Article  Google Scholar 

  5. Kirkham, J. J. et al. PLoS Med. 14, e1002447 (2017).

    Article  Google Scholar 

  6. Calvert, M. et al. JAMA 319, 483–494 (2018).

    Article  Google Scholar 

  7. Trotti, A. et al. Semin. Radiation Oncol. 13, 176–181 (2003).

    Article  Google Scholar 

  8. Basch, E. et al. J. Natl Cancer Inst. 101, 1624–1632 (2009).

    Article  Google Scholar 

  9. Kluetz, P. G. et al. Am. Soc. Clin. Oncol. Educ. Book 35, 67–73 (2016).

    Article  Google Scholar 

  10. Chen, A. C., Mitchell, S. A., Minasian, L. M. & St. Germain, D. in Novel Designs of Early Phase Trials for Cancer Therapeutics (ed. Takimoto, K. A.) 193–208 (Elsevier, 2018).

  11. Dueck, A. C. et al. JAMA Oncol. 1, 1051–1059 (2015).

    Article  Google Scholar 

  12. Trask, P. C. et al. Clin. Trials 15, 616–623 (2018).

    Article  Google Scholar 

  13. Shepshelovich, D. et al. Oncologist 24, e146–e148 (2019).

    Article  Google Scholar 

  14. Pearman, T. P. et al. Cancer 124, 991–997 (2018).

    Article  Google Scholar 

  15. FDA. Core Patient-Reported Outcomes in Cancer Clinical Trials: Draft Guidance for Industry (June 2020 draft); https://www.fda.gov/regulatory-information/search-fda-guidance-documents/core-patient-reported-outcomes-cancer-clinical-trials (FDA, 2021).

  16. Chalasani, M., Vaidya, P. & Mullin, T. Res. Involve. Engagement 4, 10 (2018).

    Article  Google Scholar 

  17. FDA. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims; https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims (FDA, 2009).

  18. Proceedings of Patient Reported Outcome Measures (PROMs) Conference Birmingham 2018. J. Patient Rep. Outcomes 2, 58 (2018).

  19. UK Medicines and Healthcare Products Regulatory Agency. Innovative Licensing and Access Pathway https://www.gov.uk/guidance/innovative-licensing-and-access-pathway (accessed 13 December 2021).

  20. Kluetz, P. G., O’Connor, D. J. & Soltys, K. Lancet Oncol. 19, e267–e274 (2018).

    Article  Google Scholar 

  21. Kluetz, P. G. et al. Value Health 21, 742–747 (2018).

    Article  Google Scholar 

  22. Tavridou, A. et al. Br. J. Clin. Pharmacol. 87, 2459–2464 (2021).

    Article  Google Scholar 

  23. West, H. JAMA Oncol. 3, 423–423 (2017).

    Article  Google Scholar 

Download references

Acknowledgements

We thank A. Filer, P. Trivedi, D. Chanouzas, S. Ghosh and A. Dueck for their advice and suggestions during this project. The author(s) disclose receipt of the following financial support for the research, authorship and/or publication of this article: This work was supported by the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Midlands-Wales Advanced Therapies Treatment Centre (MW-ATTC) program grant from Innovate UK to a consortium of partners including Health Technology Wales, the Welsh Blood Service and the University of Birmingham (grant number: IUK: 104232) and Innovate UK (part of UK Research and Innovation) grant Patient-reported outcomes assessment to support accelerated access to advanced cell and gene therapies: PROmics (grant number: 104777). The funder was not involved in any aspect of the research work. O.L.A., A.R. and M.C. receive funding from the NIHR Applied Research Collaboration, West Midlands (ARC), and the Brain Tumour Charity. O.L.A, receives funding from the NIHR Birmingham Biomedical Research Centre (BRC, West Midlands at the University of Birmingham) and University Hospitals Birmingham NHS Foundation, Innovate UK (part of UK Research and Innovation), Gilead Sciences Ltd. and Janssen Pharmaceuticals Inc. MC is Director of the Birmingham Health Partners Centre for Regulatory Science and Innovation, Director of the Centre for Patient Reported Outcomes Research and is a National Institute for Health Research (NIHR) Senior Investigator. She receives funding from the NIHR, UK Research and Innovation (UKRI), NIHR Birmingham Biomedical Research Centre, the NIHR Surgical Reconstruction and Microbiology Research Centre and UK SPINE at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Health Data Research UK, Innovate UK (part of UKRI), Macmillan Cancer Support, UCB, Gilead, Janssen and GSK Pharma. The views expressed in this article are those of the authors and not necessarily those of the NIHR, the Department of Health and Social Care or the MHRA.

Author information

Authors and Affiliations

  1. Centre for Patient Reported Outcomes Research, Institute of Applied Health Research, University of Birmingham, Birmingham, UK

    Ameeta Retzer, Olalekan Lee Aiyegbusi & Melanie Calvert

  2. National Institute for Health Research Applied Research Centre West Midlands, University of Birmingham, Birmingham, UK

    Ameeta Retzer, Olalekan Lee Aiyegbusi & Melanie Calvert

  3. National Institute for Health Research Birmingham Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

    Olalekan Lee Aiyegbusi, Anna Rowe, Philip N. Newsome, Sheeba Khan & Melanie Calvert

  4. Birmingham Health Partners Centre for Regulatory Science and Innovation, Birmingham, UK

    Olalekan Lee Aiyegbusi & Melanie Calvert

  5. Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK

    Anna Rowe & Jessica Douglas-Pugh

  6. Centre for Liver and Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK

    Philip N. Newsome & Sheeba Khan

  7. Liver Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

    Sheeba Khan

  8. University of Birmingham, Birmingham, UK

    Saloni Mittal

  9. NCRI Consumer Forum National Cancer Research Institute, London, UK

    Roger Wilson

  10. Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK

    Daniel O’Connor & Lisa Campbell

  11. Outcomes Research Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA

    Sandra A. Mitchell

  12. National Institute for Health Research Surgical Reconstruction and Microbiology Research Centre, University of Birmingham, Birmingham, UK

    Melanie Calvert

  13. UK SPINE, University of Birmingham, Birmingham, UK

    Melanie Calvert

Authors
  1. Ameeta Retzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olalekan Lee Aiyegbusi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anna Rowe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Philip N. Newsome
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jessica Douglas-Pugh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sheeba Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Saloni Mittal
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Roger Wilson
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Daniel O’Connor
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Lisa Campbell
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Sandra A. Mitchell
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Melanie Calvert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Melanie Calvert.

Ethics declarations

Competing interests

O.L.A. declares personal fees from Gilead Sciences Ltd., GlaxoSmithKline (GSK) and Merck outside the submitted work. M.C. has received personal fees from Astellas, Aparito Ltd., CIS Oncology, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK and the Patient-Centered Outcomes Research Institute (PCORI) outside the submitted work. The other authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Retzer, A., Aiyegbusi, O.L., Rowe, A. et al. The value of patient-reported outcomes in early-phase clinical trials. Nat Med 28, 18–20 (2022). https://doi.org/10.1038/s41591-021-01648-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-021-01648-4

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing